Allos Therapeutics, Inc.'s FOLOTYN(R) Data to be Presented at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming international medical conferences: the 16th Congress of the European Hematology Association (EHA) in London, England from June 9-12, and the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland from June 15-18.

Back to news